Advertisement

Topics

Global Market Study on Malignant Mesothelioma: Cisplatin and Combination Segment Projected to be the Second Most Lucrative Segment by Drug Type

08:48 EDT 9 Aug 2017 | PR Newswire

NEW YORK, Aug. 9, 2017 /PRNewswire/ -- An introduction to the report

All the information pertaining to the market of this rare form of cancer is provided in our recently published report "Malignant Mesothelioma Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025)." Caused due to the exposure to toxic asbestos, the occurrence of this cancer is higher in countries such as Russia and China. These two countries are pegged to represent the most lucrative markets, owing to the relatively high production of asbestos in these countries. Besides, a high consumption of asbestos in the APAC region is expected to create a sizeable opportunity for key players in this market. Our analysts have observed that the rapid substitution through generics to ease availability and affordability is the key focus area in the global malignant mesothelioma market. We have observed that the application of combination therapies is gaining traction in the market across regions. Documented evidence on the adoption of combination treatments and benefits is being made available to ease patients' journey through the treatment process. According to our analysts, there is a great need in the market to efficiently meet the requirements for the present treatment regimen. The drugs that are currently in use do not show much response rates. The malignant mesothelioma treatment market requires drugs to increase the current survival rate.

Download the full report: https://www.reportbuyer.com/product/5056919/

Acquisitions and collaborations are the key strategies adopted by players to develop molecules for the better treatment of malignant mesothelioma. Companies are focusing on collaborating with established research centers and other cancer drug manufacturers to develop drugs. Our research indicates that the hospital pharmacies distribution channel segment is expected to witness a significant rise in revenue share over the forecast period, owing to the increasing direct procurement of mesothelioma drugs by governments to ensure availability in hospital pharmacies and oncology centers.

We have used our in-house epidemiology data based model to estimate the global malignant mesothelioma market numbers

Weighted average selling price has been considered to estimate the market size of various drugs mentioned in the scope of the study. Price per country is captured with the local currency. The local currency figures are then converted to USD to offer forecasts in a consistent currency standard. We have also considered the latest annual exchange rate to reflect the impact of the most recent economic conditions. Prices considered in the models are standardized based on the average dosage used per malignant mesothelioma treatment per dosage cycle of six months. Availability of branded off-patent equivalents has been taken into consideration while calculating prices. We have adopted the bottom-up approach to forecast the malignant mesothelioma market globally. Besides this, forecasting is done using our internal proprietary model that considers different macro-economic factors, industry based demand driving factors impacting the market and the relevant forecast trends apart from disease related factors.

Market Taxonomy

Drug Type

Pemetrexed
Cisplatin
Carboplatin
Gemcitabine
Vinorelbine
Others

Route of Administration

Oral
Parenteral

Region

North America
Latin America
Europe
APAC
MEA

Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Oncology Centers

Research Methodology

Download the full report: https://www.reportbuyer.com/product/5056919/

About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.com

For more information:

Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48

Website: www.reportbuyer.com

View original content:http://www.prnewswire.com/news-releases/global-market-study-on-malignant-mesothelioma-cisplatin-and-combination-segment-projected-to-be-the-second-most-lucrative-segment-by-drug-type-300502038.html

SOURCE ReportBuyer

NEXT ARTICLE

More From BioPortfolio on "Global Market Study on Malignant Mesothelioma: Cisplatin and Combination Segment Projected to be the Second Most Lucrative Segment by Drug Type"

Quick Search
Advertisement
 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...